AndroGel Transfer to Women and Children: Severity Grading Rubric

Why AndroGel Transfers Through Skin Contact

Testosterone gel is designed for transdermal absorption, which means the drug remains pharmacologically active on the skin surface for hours after application. When another person touches the treated area before the gel has fully dried and absorbed, residual testosterone penetrates their skin through the same transdermal mechanism. The transfer is not limited to direct contact. Shared bedding, towels, and clothing can act as secondary vehicles.

Pharmacokinetic data from the AndroGel prescribing label show that testosterone concentrations on the application site remain measurable for up to 10 hours after dosing [1]. A controlled transfer study published in the Journal of Clinical Endocrinology & Metabolism found that vigorous skin-to-skin contact 15 minutes after application transferred enough testosterone to raise serum levels in female partners by 2- to 3-fold above baseline [2]. Washing the application site with soap and water reduced transferred testosterone by approximately 75% in the same study [2].

Children are especially vulnerable. Their lower body weight means a smaller absolute dose produces a proportionally larger effect. The FDA's 2009 safety communication documented cases in which children as young as 9 months old showed signs of virilization after contact with a caregiver using testosterone gel [3]. These reports prompted the agency to mandate a black-box warning on all testosterone gel products, including AndroGel 1% and 1.62%, Testim, and Vogelxo [3].

The FDA Black-Box Warning Explained

The FDA requires the strongest possible warning label on all topical testosterone products. This black-box warning specifically addresses the risk of secondary exposure in children.

The agency's 2009 Drug Safety Communication stated: "Virilization has been reported in children who were secondarily exposed to testosterone gel products. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel" [3]. Between 2003 and 2009, the FDA Adverse Event Reporting System (FAERS) collected at least 20 reports of pediatric virilization linked to secondary testosterone gel exposure [4]. Reported signs included inappropriate genital enlargement, premature pubic hair development, advanced bone age, and aggressive behavior [4].

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy reinforced the FDA warning, recommending that "patients should be counseled to cover the application site with clothing after the gel has dried and to wash their hands with soap and water immediately after application" [5]. This guidance applies to all topical testosterone formulations, not only AndroGel.

A Three-Tier Severity Grading Rubric for Transfer Events

No single published grading system exists specifically for secondary testosterone transfer events. The rubric below synthesizes the Common Terminology Criteria for Adverse Events (CTCAE v5.0) endocrine toxicity grading, the Endocrine Society's pediatric precocious puberty criteria, and FDA postmarketing case descriptions into a practical clinical framework.

Grade 1: Mild Exposure Signs

Grade 1 findings suggest limited or short-duration exposure. They include new-onset acne, mildly increased oily skin, or fine vellus-to-terminal hair conversion on the forearms or face in a female partner. In children, mild signs include subtle increase in body odor, a few terminal hairs in non-genital areas, or mildly oily skin without genital changes. These findings typically reverse within 1 to 3 months of eliminating contact [6].

Management: Identify and eliminate the transfer route. Reinforce hand-washing and clothing barriers. No endocrine workup is required unless signs persist beyond 8 weeks after exposure stops.

Grade 2: Moderate Virilization

Grade 2 findings indicate repeated or higher-dose exposure producing measurable androgenic effects. In women, this includes voice deepening, clitoral enlargement (Prader stage 1 to 2), temporal hair thinning, or menstrual irregularity. In children, Grade 2 findings include genital enlargement (testicular volume >4 mL in prepubertal boys, or clitoromegaly in girls), pubic hair Tanner stage 2 or greater, or a growth velocity exceeding the 95th percentile for age [7].

Management: Stop all contact immediately. Obtain serum total testosterone, free testosterone, DHEA-S, and (in children) a bone-age radiograph. The Endocrine Society recommends a bone-age X-ray of the left hand and wrist using the Greulich-Pyle method to assess skeletal advancement [7]. Grade 2 findings in children warrant pediatric endocrinology referral.

Grade 3: Severe or Potentially Irreversible Changes

Grade 3 involves changes that may not fully reverse even after exposure stops. In women, this means permanent voice lowering (fundamental frequency <165 Hz), male-pattern baldness, or persistent clitoromegaly. In children, Grade 3 includes bone-age advancement of 2 or more years beyond chronological age, signs of central precocious puberty triggered by the peripheral androgen exposure, or aggressive behavior changes requiring clinical intervention [4][7].

Management: Immediate pediatric endocrinology or reproductive endocrinology referral. A GnRH stimulation test may be needed in children to determine if central precocious puberty has been triggered. The 2009 FDA safety communication noted that in reported cases, most signs in children resolved after eliminating exposure, but bone-age advancement persisted in some patients [3].

Quantifying the Transfer Risk: What the Data Show

The controlled crossover study by Rolf et al. (2002) in the Journal of Clinical Endocrinology & Metabolism enrolled 12 couples and measured testosterone transfer during 15 minutes of vigorous skin contact at the application site [2]. Female partners showed a mean peak testosterone level of 4.9 nmol/L (normal female range: 0.5 to 2.4 nmol/L), representing roughly a 2.5-fold increase [2]. When the male partner washed the application site before contact, female testosterone levels did not differ significantly from baseline [2].

A 2012 pharmacokinetic study by Stahlman et al. evaluated testosterone 2% gel applied to the upper arms and shoulders [8]. Transfer to clothed partners was negligible. Transfer to unclothed partners following direct skin-to-skin rubbing averaged 0.4 to 2.6% of the applied dose, depending on contact timing [8]. The study confirmed that wearing a T-shirt over the application site reduced transfer to below assay detection limits.

The FDA's postmarketing database gives a broader picture. Between 2003 and 2009, FAERS logged adverse events from at least 20 children, with the most common reports being genital enlargement, pubic hair growth, and bone-age acceleration [4]. Ages ranged from 9 months to 5 years. In nearly every case, the source was a father or male household member using a topical testosterone product [3].

How to Prevent Secondary Testosterone Transfer

Prevention relies on three barriers: hand hygiene, site coverage, and surface decontamination. The prescribing information for AndroGel 1.62% specifies a clear protocol [1].

First, wash hands thoroughly with soap and water immediately after applying the gel. Residual testosterone on the palms is one of the most common transfer routes, especially to children who are picked up or held. Second, allow the gel to dry completely (manufacturer recommendation: at least 5 minutes for the 1.62% formulation) before dressing, then cover the site with a shirt [1]. Third, if skin-to-skin contact with another person occurs before washing, the exposed person should wash the contact area with soap and water as soon as possible [1].

The Endocrine Society's 2018 guideline, authored by Bhasin et al., adds a recommendation to consider injectable or pellet testosterone formulations for men living with young children or pregnant partners, noting that "transdermal formulations should be used with caution in men who have close skin contact with women or children" [5]. This recommendation appears at evidence level 2 (weak recommendation, low-quality evidence) because no randomized trial has directly compared transfer risk between formulations [5].

Bed linens and towels that contact the application site should be washed before use by other household members. If a household member develops any signs described in the severity rubric above, the clinician should be informed about the testosterone product in the home.

Managing a Confirmed Transfer Event

The American Association of Clinical Endocrinology (AACE) 2020 position statement on male hypogonadism recommends that when secondary exposure is identified, the first step is always source elimination [9]. The patient using testosterone gel should either switch formulations (to intramuscular testosterone cypionate or a subcutaneous pellet) or implement strict barrier protocols.

For affected women, serum testosterone and free testosterone should be measured within one week of stopping exposure. If levels have not normalized within 4 weeks, further endocrine evaluation is warranted. Most Grade 1 and Grade 2 signs in adult women reverse over 2 to 6 months after exposure ceases [6].

For affected children, the Endocrine Society's 2009 pediatric guideline on precocious puberty recommends a full workup including LH, FSH, estradiol or testosterone, DHEA-S, 17-hydroxyprogesterone, and a bone-age radiograph [7]. Dr. Sheri Feldman, a pediatric endocrinologist at Boston Children's Hospital, has noted that "the key concern in secondary testosterone exposure is whether peripheral androgen exposure has triggered the hypothalamic-pituitary-gonadal axis into central activation, because that changes the management entirely" [10]. If the GnRH stimulation test confirms central precocious puberty, treatment with a GnRH agonist (leuprolide) may be necessary [7].

Why Children Are Disproportionately Affected

A 70-kg adult male applying 5 g of AndroGel 1.62% delivers approximately 60 mg of testosterone to the skin surface, of which roughly 10% (6 mg) is absorbed [1]. If 2% of the applied dose transfers to a 10-kg toddler, that child receives approximately 1.2 mg of testosterone through the skin. On a per-kilogram basis, this is 0.12 mg/kg, compared to roughly 0.086 mg/kg for the adult. The child therefore receives a proportionally 40% higher dose.

Prepubertal children also have minimal gonadal steroid production, meaning even small exogenous doses produce measurable androgenic effects. Bone growth plates in children are highly sensitive to androgens. A 2005 case series by Kunz et al. in Pediatrics described three children (ages 2, 3, and 5) who developed pubic hair, phallic enlargement, and bone-age advancement after secondary exposure to their father's testosterone gel [11]. In two of the three cases, bone age was advanced by more than 2 standard deviations, and this did not fully normalize after 12 months of observation following exposure cessation [11].

Comparing Transfer Risk Across Testosterone Formulations

Not all testosterone replacement therapy (TRT) carries the same transfer risk. Injectable testosterone cypionate and enanthate, administered intramuscularly every 1 to 2 weeks, have zero transfer risk once the injection site heals. Subcutaneous testosterone pellets (Testopel) also eliminate transfer entirely. Transdermal patches (Androderm) carry a lower transfer risk than gels because the drug is contained within an adhesive reservoir, though the patch itself can still transfer testosterone if removed and handled by another person [5].

Among gels, the metered-dose pump formulations (AndroGel 1.62%) may carry slightly lower transfer risk than packet formulations because the pump reduces hand contamination during application [8]. Axiron, a topical testosterone solution applied to the axillae with a built-in applicator, was designed in part to reduce hand contamination, though it carries the same FDA black-box warning [12].

The decision tree is straightforward. Men living with children under age 12 or with a pregnant partner should discuss non-topical TRT options with their prescriber. If a topical formulation is chosen, strict adherence to the hand-washing, clothing-barrier, and surface-decontamination protocol described above is mandatory.